Incyte replaces CEO Hoppenot with dealmaker Meury
BioPharma Drive: Drug Pricing
JUNE 26, 2025
Published June 26, 2025 Ned Pagliarulo Lead Editor post share post print email license An Incyte researcher works in a laboratory. But Jakafi’s main patents expire in 2028, a date that for years now has been on investors’ radar as they’ve pressed Incyte on what it expects will take the drug’s place. You can unsubscribe at anytime.
Let's personalize your content